Corton Capital Inc. Invests $264,000 in Progyny, Inc. (NASDAQ:PGNY)

Corton Capital Inc. bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 15,323 shares of the company's stock, valued at approximately $264,000.

Other large investors have also recently modified their holdings of the company. River Road Asset Management LLC bought a new stake in shares of Progyny in the 4th quarter valued at $25,529,000. Pacer Advisors Inc. boosted its holdings in Progyny by 47.5% in the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock worth $63,414,000 after acquiring an additional 1,183,558 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its position in Progyny by 90.1% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after purchasing an additional 695,740 shares during the period. Barclays PLC increased its position in shares of Progyny by 95.7% during the fourth quarter. Barclays PLC now owns 1,382,205 shares of the company's stock worth $23,843,000 after acquiring an additional 676,048 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in Progyny during the 4th quarter worth approximately $10,557,000. Institutional investors own 94.93% of the company's stock.

Progyny Price Performance

Progyny stock traded down $2.17 during mid-day trading on Friday, hitting $21.20. The company's stock had a trading volume of 3,566,405 shares, compared to its average volume of 1,751,362. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of 36.55, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $30.42. The business has a 50 day moving average price of $21.95 and a 200-day moving average price of $19.51.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm had revenue of $324.04 million for the quarter, compared to analysts' expectations of $307.86 million. During the same period in the previous year, the company earned $0.17 EPS. The company's quarterly revenue was up 16.5% on a year-over-year basis. On average, equities research analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a report on Monday, March 31st. Bank of America boosted their target price on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Canaccord Genuity Group raised their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. Finally, JPMorgan Chase & Co. upped their price target on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Progyny has an average rating of "Hold" and a consensus price target of $23.64.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.